Converting to IDegLira is efficacious regardless of pre-trial insulin dose in patients with type 2 diabetes uncontrolled on insulin glargine U100

被引：0
|
作者：
Meneghini, L. F. [1 ]
Jaeckel, E. [2 ]
Leiter, L. A. [3 ]
Lingvay, I. [1 ]
Harvey, J. N. [4 ]
Begtrup, K. [5 ]
Chandarana, K. [5 ]
Vilsboll, T. [6 ,7 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Hannover Med Sch, Hannover, Germany
[3] Univ Toronto, Toronto, ON, Canada
[4] Bangor Univ, Wrexham, Wales
[5] Novo Nordisk AS, Soborg, Denmark
[6] Univ Copenhagen, Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[7] Gentofte Univ Hosp, Ctr Diabet Res, Copenhagen, Denmark
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
671
引用
收藏
页码：S306 / S306
页数：1
相关论文
共 50 条
  • [41] SWITCH 2: reduced risk of hypoglycaemia with insulin degludec vs insulin glargine U100 in a type 2 diabetes population on basal insulin: a randomised, double-blind, crossover trial
    Wysham, C.
    Bhargava, A.
    Chaykin, L. B.
    de la Rosa, R.
    Handelsman, Y.
    Troelsen, L. N.
    Kvist, K.
    Norwood, P.
    DIABETOLOGIA, 2016, 59 : S43 - S44
  • [42] COST-UTILITY ANALYSIS OF INSULIN DEGLUDEC VS. INSULIN GLARGINE U100 TREATMENT IN PATIENTS WITH DIABETES MELLITUS TYPE 1 AND 2 IN SERBIA
    Culic, M.
    Russel-Szymczyk, M.
    Chubb, B.
    Tikkanen, C.
    VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [43] Efficacy and safety of switching to insulin icodec, a once-weekly basal insulin, vs insulin glargine U100 in patients with type 2 diabetes inadequately controlled on OADs and basal insulin
    Bajaj, H.
    Isendahl, J.
    Gowda, A.
    Stachlewska, K.
    Rosenstock, J.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S317 - S317
  • [44] Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study
    Natalia Duque
    Esther Artime
    Irene Romera
    Jeremie Lebrec
    Silvia Díaz
    Miriam Rubio
    Antoni Sicras-Mainar
    Enrique Carretero-Anibarro
    Xavier Mundet
    Juan J. Gorgojo-Martínez
    Jesús Reviriego
    Advances in Therapy, 2021, 38 : 3857 - 3871
  • [45] Efficacy and Safety of Insulin Degludec (IDeg) vs. Insulin Glargine U100 (IGlar) in Hispanic Patients with Type 2 Diabetes (T2D)
    Chaykin, Louis B.
    Bhargava, Anuj
    Wysham, Carol H.
    Abrahamsen, Trine
    Van Leeuwen, Michiel
    De la Rosa, Raymond
    DIABETES, 2017, 66 : A617 - A617
  • [46] Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus
    Lucidi, Paola
    Porcellati, Francesca
    Cioli, Patrizia
    Candeloro, Paola
    Andreoli, Anna Marinelli
    Bolli, Geremia B.
    Fanelli, Carmine G.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (01) : 57 - 61
  • [47] A SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE U100 AND INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN
    Zhou, L.
    Zhou, N.
    Hu, M.
    VALUE IN HEALTH, 2022, 25 (07) : S386 - S386
  • [48] IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting
    Hunt, Barnaby
    Mocarski, Michelle
    Valentine, William J.
    Langer, Jakob
    DIABETES THERAPY, 2017, 8 (03) : 531 - 544
  • [49] SWITCH 1: reduced risk of hypoglycaemia with insulin degludec vs insulin glargine U100 in patients with type 1 diabetes: a randomised, double-blind, crossover trial
    Lane, W.
    Bailey, T. S.
    Gerety, G.
    Gumprecht, J.
    Philis-Tsimikas, A.
    Hansen, C. T.
    Nielsen, T. S. S.
    Warren, M. L.
    DIABETOLOGIA, 2016, 59 : S42 - S43
  • [50] IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting
    Barnaby Hunt
    Michelle Mocarski
    William J. Valentine
    Jakob Langer
    Diabetes Therapy, 2017, 8 : 531 - 544
12345